Scholars Central

Research articlePublished 6 Mar 2018

Synergistic Inhibition of Multiple Myeloma Growth by Anti-CD138-Interferon-alpha14 Fusion Protein and Lenalidomide

Authors: Kham R Trinh, Alex Vasuthasawat, Reiko Yamada King, John M Timmerman, Sherie L Morrison

1Department of Microbiology, Immunology and Molecular Genetics, University of California los Angeles, Los Angeles, CA, USA; 2Molecular Biology Institute, UCLA, Los Angeles, CA, USA; 3Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA; 4Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA

Journal of Molecular Immunology

Volume 3 · Issue 1 · Pages 1–9

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Although recent advances have improved the management of multiple myeloma, it remains an incurable malignancy. We now demonstrate that anti-CD138 genetically fused to interferon alpha14 (IFNα14) synergizes with the approved therapeutic lenalidomide in arresting the proliferation of the human multiple myeloma cell line NCIH929 both in vitro and in vivo. This synergism is the consequence of the combined effects of multiple, complementary anti-tumor activities including potentiated activation of STAT1 and downregulation of c-Myc, interferon regulatory factor 4 (IRF4) and poly(ADP-ribose) polymerase 1 (PARP-1). Caspase activation and glucose utilization also play a role in the induction of apoptosis by lenalidomide+anti-CD138-IFNα14 as inhibition of caspase activation, glycolysis or oxidative phosphorylation (OXPHOS) decreased but did not eliminate the apoptosis seen following treatment. Treatment with lenalidomide+anti-CD138-IFNα14 results in replicative stress resulting from increased accumulation of reactive oxygen species (ROS). Unexpectedly, we observed that the cellular stress elicited by treatment with lenalidomide or lenalidomide+anti-CD138-IFNα14 results in the degradation of Chk1, the Ser/Thr kinase central to the genome surveillance pathways of the DNA damage response and cell cycle checkpoints. Using an in vivo xenograft model we found that treatment with anti-CD138-IFNα14+lenalidomide was much more effective than either treatment alone with approximately 40% (9/24) of the animals with established tumors cured. Based on our findings, clinical testing of combination therapy with lenalidomide and anti-CD138-IFN fusion proteins for the treatment of multiple myeloma may be merited.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Molecular Immunology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Molecular Immunology
  • SubjectGenetics & Molecular Biology
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Kham R Trinh”
  • BylineArticles whose byline prints “Alex Vasuthasawat”
  • BylineArticles whose byline prints “Reiko Yamada King”
  • BylineArticles whose byline prints “John M Timmerman”
  • BylineArticles whose byline prints “Sherie L Morrison”